TEST:

HDPCR NSCLC RUO Assay

"ChromaCode, Inc....today announced a strategic partnership with Protean BioDiagnostics Inc...This partnership's goal is to introduce a non-small cell lung cancer (NSCLC) assay, based on ChromaCode's state-of-the-art High Definition PCR (HDPCR™) multiplexing technology, via an early access program....The ultimate goal of the strategic partnership between ChromaCode and Protean is to extend the benefits of affordable and easily accessible assays that ensure rapid and precise diagnoses to a diverse range of patients in both Florida and the rest of the USA."

"ChromaCode...announced an early-access commercial launch of a non-small-cell lung cancer assay based on innovative High Definition PCR (HDPCR™) technology. Non-small-cell lung cancer (NSCLC) is the most common cancer of the lung, accounting for approximately 85% of the more than 230,000 lung cancer diagnoses in the United States each year, and has a five-year survival rate of only 25.4 %, according to the National Cancer Institute."

"ChromaCode...announced today a partnership with MedGenome, to bring its innovative High Definition PCR (HDPCR™) multiplexing technology to India and the Middle East. With the size of the Indian genomics market estimated to reach $2.7 billion by 2023, there is an unmet need for advanced yet affordable molecular diagnostics solutions that can reach a broader population."